Blaze Bioscience, Inc.

Allozyne, Inc.

Fred Hutchinson Cancer Center

Medimmune Limited

Natalie Winblade Nairn

Julia E Novak

Dennis M Miller

Scott R Presnell

Kenneth H Grabstein

Mark R Stroud

Claudia Jochheim

Christopher Mehlin

James M Olson

Colin Correnti

Roland K Strong

Thomas Graddis

Aijun Wang

Deepshikha Datta

Stacey J Hansen

Stephen McCraith

Andrea Wang

Valorie R Wiss

Andrew David Strand

Kelly Byrnes-Blake

Emily June Girard

William Brady

Gordon E King

Michael Peter Vanbrunt

Hengyu Xu

Gordon King

Kurt David Shanebeck

Paul Heffner Slagle

Greg T Hermanson

Kenneth Grabstein

Kenneth Christopher Thornton

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

Tissue-homing peptide conjugates and methods of use thereof

Peptide-immuno-oncology agent complexes ('peptide-I/O complexes') that can home, target, migrate to, are directed to, are retained by, accumulate in, penetrate, or bind to the tumor microenvironment, tumor tissues, or cells or compartments or cytosol of cells thereof, or any combination thereof, are disclosed. Additionally disclosed are peptide-I/O complexes that can cross the blood-brain barrier. Pharmaceutical compositions and uses for peptide-I/O complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an immuno-oncology agent (“I/O”) to the tumor microenvironment. Targeted compositions of the disclosure can deliver peptide-I/O complexes to target regions, tissues, structures or cells targeted by the peptide.

Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

Cartilage-homing peptides

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptide-active agent conjugates are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the kidney. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.

Renal-homing peptide conjugates and methods of use thereof

Cartilage-homing peptide conjugates and methods of use thereof

The invention relates inter alia to a bivalent, bispecific construct comprising an anti-IL-6 antibody, or derivative thereof, and an anti-IL-23 antibody, or derivative thereof and its use in therapy. The invention also relates to useful anti-IL-6 antibodies and anti-IL-23 antibodies.

Antibody derivatives

The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

Modified human interferon-beta polypeptides

Methods of modifying polypeptides comprising non-natural amino acids

Modified human interferon-&#x3b2; polypeptides

Growing community of inventors

Seattle, WA, United States of America

Natalie Winblade Nairn